▣ RecallGuard

OFFICIAL-SOURCE RECALL · AUSTRALIA

Pertuzumab 420mg in 0.9% Sodium Chloride in Polyolefin Bag Recall: Classification Class II Reason for the

Use the identifiers printed on your item to determine whether this recall may affect the product you own.

CountryAustraliaPublishedAugust 7, 2026Last updatedAugust 7, 2026Official source last checkedAugust 26, 2026 at 7:44 PM UTC

CHECK THE ITEM YOU OWN

Is your product affected?

Brand
See official notice
Product
Pertuzumab 420mg in 0.9% Sodium Chloride in Polyolefin Bag (Freeflex) for Intravenous Infusion
Manufacturer
See official notice
Lot number
numbers, BB26084718
Batch number
numbers, BB26084718
Date code
dates, Date
Expiration date
dates, Date

The barcode may identify the product type, while the recall may apply only to certain lots, dates or variants. Check all identifiers listed in the official recall.

Why this product was recalled

Classification Class II Reason for the Action Cairns Hospital reported on 11/08/2026 that a Pertuzumab infusion bag (BB26084718) had expired prior to treatment. The single dose unit had expired during transit to the customer. The customer advised the single dose unit was not administrated and discarded. A replacement unit was provided to the customer. This recall does not affect any other compounded batches of Pertuzumab or any other Slade Health products. Given the nature of the product, this action was undertaken prior to TGA notification (Immediate Market Action as defined within the PRAC). Instructions for Customers/Users - The product has been discarded by the customer. - A replacement product has been provided to the customer. Action Commencement Date 17/08/2026 Responsible Entity Slade Health Pty Ltd

Hazard

Classification Class II Reason for the Action Cairns Hospital reported on 11/08/2026 that a Pertuzumab infusion bag (BB26084718) had expired prior to treatment. The single dose unit had expired during transit to the customer. The customer advised the single dose unit was not administrated and discarded. A replacement unit was provided to the customer. This recall does not affect any other compounded batches of Pertuzumab or any other Slade Health products. Given the nature of the product, this action was undertaken prior to TGA notification (Immediate Market Action as defined within the PRAC). Instructions for Customers/Users - The product has been discarded by the customer. - A replacement product has been provided to the customer. Action Commencement Date 17/08/2026 Responsible Entity Slade Health Pty Ltd

Official recall notice

Pertuzumab 420mg in 0.9% Sodium Chloride in Polyolefin Bag (Freeflex) for Intravenous Infusion

Agency: Therapeutic Goods Administration

Official publication date: August 7, 2026

Read the official AU_TGA_DRAC recall notice →

Scan products you own

Scan products you own once and let RecallGuard monitor future official recalls.

Scan & Monitor Products

Browse connected recall information